LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Elenco Azioni・uniQure NV

uniQure NV

Chiusa

26.7 -4.91

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

26.23

Massimo

28.08

Metriche Chiave
By Trading Economics
Entrata	-16M -54M
Vendite	-2M 3.6M
EPS	-0.73
Margine di Profitto	-1,502.948
Dipendenti	221
EBITDA	13M -36M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+49.22% upside

Dividendi
By Dow Jones
Utili prossimi	28 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	476M 1.8B
Apertura precedente	31.61
Chiusura precedente	26.7

uniQure NV Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 mar 2026, 13:13 UTC

I principali Market Mover

UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

9 gen 2026, 15:14 UTC

I principali Market Mover

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3 nov 2025, 13:34 UTC

I principali Market Mover

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24 set 2025, 18:51 UTC

Utili

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Confronto tra pari

Modifica del prezzo

uniQure NV Previsione

Obiettivo di Prezzo

By TipRanks

49.22% in crescita

Previsioni per 12 mesi

Media 42.11 USD 49.22%

Alto 95 USD

Basso 14 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per uniQure NV - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a uniQure NV - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.